Artemisinin Combination Therapy Market Share, Size | 2022-27
Market Overview:
Over the forecast period, 2022–2027, the artemisinin combination therapy market is anticipated to grow at a CAGR of 8.31%.
Market expansion was significantly impacted by the COVID-19 pandemic. The disruption of health systems and malaria control programmes brought on by COVID-19, particularly in sub-Saharan Africa, was disproportionately burdening children and pregnant women, according to the article “Identifying and combating the impacts of COVID-19 on malaria” that was published in July 2020. The main reason for this was that the COVID-19 pandemic was making it difficult to diagnose malaria because the two diseases share some symptoms. These reasons led to the expectation that the COVID-19 pandemic would have an impact on the market for artemisinin combination therapies.
Scope of the Report:
According to the study’s focus, artemisinin, a plant derivative isolated from the sweet wormwood plant Artemisia annua, is known to quickly and effectively lower the level of plasmodium parasites in the blood of malaria patients. ACT, or artemisinin-combination therapy, is used to treat malaria caused by Plasmodium falciparum. The Artemisinin Combination Therapy Market is divided into two categories: Geography and Combination Therapy Type (including artemether-lumefantrine, artesunate-amodiaquine, artesunate-pyronaridine, artesunate-sulfadoxine-pyrimethamine, and others) (Asia-Pacific, South America, Middle East and Africa, and Rest of the World). The report provides the value for the aforementioned segments (in USD million).
Comments
Post a Comment